An Important Skin Cancer Prevention Reminder: Don’t Fry

Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are treated for various forms of the disease.

Skin cancer types include basal and squamous cell cancers, as well as melanoma, the deadliest form of skin cancer. About 73,870 Americans are expected to be diagnosed with melanoma this year. Survival rates are significantly higher when the disease is diagnosed at its earliest stage.

Read More

Why We Need Tailored Tobacco-control Strategies

Cigarette smoking is linked to 18 different types of cancer. It is the leading preventable cause of cancer in the United States, accounting for 19 percent of the 1,570,978 cancers diagnosed in U.S. adults ages 30 and older in 2014, according to the latest research. Another 0.4 percent of the cancer diagnoses in the U.S. that year were attributable to exposure to secondhand smoke.

That’s why February, which is National Cancer Prevention Month, is a good time to raise awareness of the dangers of cigarette smoking and exposure to secondhand smoke.

Read More

Could Genomics Influence Prostate Cancer Treatment?

Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed with prostate cancer have a tumor that grows very slowly, making it very unlikely that the disease will progress to become a clinical problem. Characterizing new ways to identify these cancers is an area of active research investigation.

Read More

Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

Recent Advances in Measuring Response to Immune Checkpoint Inhibitors

In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to treat 10 different types of cancer, in addition to solid tumors located anywhere in the body that have certain DNA damage and repair-related biomarkers. However, only a small percentage of patients respond to these treatments, and they can have significant side effects. Researchers are looking for biomarkers that can identify patients who are likely to respond to immune checkpoint inhibitors.

Read More

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies

A pair of studies published recently in journals of the American Association for Cancer Research bring to our attention the unexpected negative consequences of combining two immunotherapeutics concurrently, and discuss the mechanisms behind improved antitumor effects and survival outcomes with sequential administration of the two drugs.

Read More